Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tesetaxel - Odonate Therapeutics

Next Previous
Drug Profile

Tesetaxel - Odonate Therapeutics

Alternative Names: DJ-927

Latest Information Update: 11 Aug 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Pharmaceutical
  • Developer Genta (CEASED); Odonate Therapeutics
  • Class Amines; Antineoplastics; Benzoates; Carbamates; Dioxolanes; Pyrimidines; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bladder cancer; Brain metastases; Breast cancer; Colorectal cancer; Gastric cancer; Malignant melanoma; Prostate cancer; Solid tumours

Most Recent Events

  • 11 Aug 2021 Genta withdraws a phase III trial in Gastric cancer (First-line therapy) prior to enrolment as the company is no longer functioning
  • 30 Jul 2021 Odonate Therapeutics terminates a phase II CONTESSA 2 trial in Breast cancer (First-line therapy, Metastatic disease, Late-stage disease, Combination therapy) in USA, Australia, Canada, Spain, South Korea, Taiwan, due to sponsor's decision to discontinue the development of trial drug (NCT03858972)
  • 30 Jul 2021 Odonate Therapeutics terminates a phase II CONTESSA TRIO trial for Breast cancer (Metastatic disease, First-line therapy, Monotherapy, Late-stage disease, In the elderly) in USA, Spain, South Korea, Poland, Germany, France and Singapore, due to sponsor's decision to discontinue the development of the trial drug (NCT03952325) (EudraCT2018-004715-41)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top